British niche medicines group AMCo is being snapped up by Canadian healthcare business Concordia for an undisclosed sum.
According to the firms, the move will create a leading, international pharmaceutical company, with products available in over 100 countries and operations in many major pharmaceutical markets.
Mark Thompson, Concordia’s chairman and chief executive, said the combination will be “truly transformational”.
“We are not only acquiring products and commercial infrastructure, but a seasoned management team who has done a fantastic job of building a solid and successful international operation”.
AMCo says the new combined business “means more patients across the world will be able to have access to the essential hard to make medicines” produced by both firms.
